Sanara MedTech Inc. Common Stock (SMTI)

FairStock Score: 28/100 — RISKY

Key Financials

Strengths

• Generates $5 million in annual free cash flow (3.0% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics

Concerns

• Trades significantly above Graham Number ($2) with negative 691% margin of safety—limited downside protection
• High leverage at 6.89x debt-to-equity increases financial risk and interest expense burden
• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Altman Z-Score of 0.9 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Sanara MedTech Inc. Common Stock is a micro-cap healthcare company valued at $177 million. Revenue stands at $107 million, though the company is currently unprofitable. From a quality standpoint, Sanara shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of 0.9 warrants caution. On valuation, the stock is commanding a steep 52.8x multiple, with trades far above its Graham Number ($2) with no margin of safety. Growth dynamics show revenue growing at 4.7% and profit growth of -4.6%. Our composite FairStock Score of 28/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Improving fundamentals and sector tailwinds could drive meaningful earnings growth, compressing the effective multiple for patient investors. With $5 million in annual free cash flow (3.0% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

At 53x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer